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Venous Lesions in Beh et's Disease 
K. SaOd=~, Z. G. Ozer*, D. Saba, M. T~ire and M. Cengiz 
Department of Cardiothoracic and Vascular Surgery, Uluda~ University Medical Faculty, Bursa, Turkey. 
Objectives: Review of venous lesions in Beh~et's disease (BD). 
Design: Retrospective study. 
Setting: University Hospital, Turkey. 
Materials and Methods: One hundred and twenty nine patients with BD diagnosed and treated in our hospital during 
the last 10 years were reviewed. Fifty-two patients with 54 vascular lesions of Beh¢et's disease were identified. 
Main Results: The incidence of isolated venous lesions in BD was 26%. Venous lesions developed after the initial diagnosis 
of BD in all patients within 10 years. Thirty-four (63%) of the 54 vascular lesions were venous and 15 (28%) were arterial. 
In 5 (9%) patients, both arterial and venous lesions were present. Deep vein thrombosis was the most frequent lesion (76%), 
followed by superficial thrombophlebitis (10%), superior vena cava thrombosis (10%) and inferior vena cava thrombosis 
(2%) and varicose veins (2%). 
Conclusions: Venous lesions are not rare and affect the prognosis of BD. For this reason, venous lesions of BD should 
always be sought at follow-up of patients with BD. 
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Introduction 
Beh~et's disease (BD) was first defined in 1937 by a 
Turkish dermatologist Hulusi Beh~et ~who described 
it as a triad of oral and genital apthes with iridocycli- 
tis. Years after, BD is thought to be a systemic 
vasculitis, probably autoimmune in origin. The close 
relationship between the prognosis of the disease and 
the complications of the cardiovascular, gastrointesti- 
nal and central nervous system have been 
postulated. 2 
Although the incidence of vascular system involve- 
ment ranges between 8-60% and venous system 
involvement between 18-24% in BD, 3 reports on 
venous system involvement are rare. 
Materials and Methods 
In our hospital 29 patients with BD have been 
diagnosed and treated in the last 10 years. Fifty-four 
vascular lesions in 52 patients of BD were identified 
(Table 1). There were 41 (76%) males and 11 (24%) 
females. The age ranged between 18-57 years with a 
*Please address all correspondence to: Prof. Ziya G6kalp Ozer, 
Uluda~ Oniversitesti, Tip Faki~ltesi G6r6kle, Bursa, Turkey. 
mean of 36. Thirty-four (63%) of the 54 vascular 
lesions were venous and 15 (28%) were arterial. In five 
(9%) patients, arterial and venous lesions were present 
concomitantly. All cases were diagnosed using the 
international criteria for BD. 4 To diagnose BD, at least 
two of the following must be present, in addition to 
recurrent apthous ulcers of the oral mucosa: ocular 
lesions, genital ulcers, positive Pathergye test (Hyper- 
reactivity of skin t6 simple trauma, such as a needle 
prick. Typicall~ a papule or a pustule forms in 24 48 
h which is positive in 60-70% of our population 2s) and 
skin signs such as erythema nodosum, acneiform 
nodules, pseudofolliculitis, papillopustulae. Subcuta- 
neous thrombophlebitis, deep vein thrombosis, epidi- 
dymitis, arterial occlusion and aneurysm, involve- 
ment of central nervous system, arthritis, positive 
family histor~ gastrointestinal system ulcers may also 
be useful in diagnosing BD. 
Deep vein thrombosis uperior and inferior vena 
cava thrombosis and varicose veins were diagnosed 
by clinical examination and contrast phelebography. 
Three patients were treated with surgical therapy and 
other cases were treated conservatively (Treatment 
was began with heparin and continued with oral 
anticoagulants or anti-aggregant drugs in addition to 
colchicin.). A filter was inserted into the vena cava 
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Table 1. Distribution of 54 vascular lesions in 52 Beh~et's disease 
No. % 
Venous 
Subcutaneous (Superficial thrombophlebitis) 4 7.6 
Lower limb deep vein thrombophlebitis 29 55.7 
Superior vena cava thrombosis 4 7.6 
Inferior vena cava thrombosis 1 1.9 
Varix 1 1.9 
Arterial 
Femoral artery aneurysm 1 1.9 
Femoral artery occlusion 5 9.6 
Crural artery occlusion 2 3.8 
Subclavian artery occlusion 1 1.9 
Iliac artery occlusion 1 1.9 
Pulmonary artery aneurysm 4 7.6 
Renal artery stenosis 1 1.9 
54 100 
Table 2. Distribution of venous lesions 
No. % 
Subcutaneous (superficial) thrombophlebitis 4 10 
Lower limb deep. vein thrombophlebitis 29 76 
Iliofemoral vein thrombophlebitis 10 26 
Femoropopliteal crural vein thrombophlebitis 9 23 
Crural vein thrombophlebitis 10 25 
Superior vena cava thrombosis 4 10 
Inferior vena cava thrombosis 1 2 
Varix 1 2 
39 100 
inferior of a patient who was given oral anticoagulants 
because of iliofemoral vein thrombosis after pulmo- 
nary emboli. In another patient with a left iliac vein 
thrombosis, whose great saphenous vein was obliter- 
ated because of phlebitis, a Palma operation with a 8 
mm PTFE on and an arteriovenous fistula was 
performed. In a patient with superior vena cava 
thrombosis, a by-pass between the right innominate 
vein and the right atrium was performed using an 8 
mm PTFE graft. 
Results 
The incidence of isolated venous lesions in BD was 
26%. Venous lesions developed after the initial diag- 
nosis of BD in all patients within ten years of follow- 
up. The distribution of 34 venous lesions and 5 venous 
lesions concomitant with arterial esions is shown in 
Table 2. Deep vein thrombosis of lower limb was the 
most common lesion (76%) followed by superficial 
thrombophlebitis (10%), superior vena cava thrombo- 
sis (10%), inferior vena cava thrombosis (2%) and 
varicose veins (2%). The location of lower limb 
involvement by deep vein thrombosis was similar 
among the iliofemoral, femoropopliteal and crural 
levels. 
Thirty-one patients howed improvement with only 
conservative treatment. In this group, follow-up 
ranged from 6 to 48 months (mean 31 months). 
Postphlebitic syndrome was observed in only four 
patients. In the patient who had insertion of an IVC 
filter, no further pulmonary emboli occured up to 28 
months follow-up. The Palma operation performed in 
the patient with severe postphlebitic syndrome, 
occluded 5 months later. The patient still uses com- 
pression stocking at 31 months follow-up. The by-pass 
procedure between the right innominate vein and 
right atrium remained patent for only six months. 
After 24 months follow-up, we observed massive 
collateral venous vessels from the right innominate 
vein to superior vena cava on venography. 
Discussion 
Although BD is rare, it appears to be more frequent in 
some Mediterranean and far Eastern countries. In 
Japan, the incidence of BD is 1/10 000. BD patients are 
generally between 20-40 years old and no gender 
predominance has been reported. 5'6 Vascular involve- 
ment in BD is seen most frequently in males (in our 
series the male/female ratio was 3.7). 3,7 
The common underlying histopatotogical lesion in 
BD is vasculitis. Mainly small and middle sized 
arteries and veins are involved in BD and the vascular 
involvement frequently causes arterial aneurysms, 
arterial occlusions, venous occlusions and varix for- 
mations. 8'9 Involvement of great arteries has been 
called vasculo-Beh~et or angio-Beh~et by some 
authors9  
The vascular lesions occur in the venous system 
(18-24%) more frequently than the arterial system 
(7%). 11 Superficial thrombophlebitis is the most com- 
mon venous lesion which occurs frequently in the 
subcutaneous tissues of the lower limb. The incidence 
ranges between 6 and 50% in the world literature. 12 
Large deep veins are affected twice as often as arteries 
(ratio 2.3 in our series). The most commonly involved 
deep veins in the order of frequency were: superior 
vena cava, inferior vena cava, femoral vein, subclavian 
vein, common iliac vein and hepatic vein. 13 The 
superior and inferior vena cava are occluded most 
frequently and they may present as vena cava superior 
syndrome or lower limb oedema. Hepatic vein 
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involvement may cause Budd-Chiari syndrome. 14
Following malignancy, BD is the commonest cause of 
superior vena cava syndrome in Mediterrenean coun- 
tries. 15 In China, the aetiologic factor in 20% of the 
patient with SVC syndrome is BD. 16 Superior and 
inferior vena cava occlusions may also cause 
death. 17 
There is no agreement about the frequency rates of 
the different venous lesions in the literature. While 
superficial thrombophlebitis is the most commonly 
encountered presentation i some reports, ~2 superior 
and inferior vena cava involvements are the most 
frequent in others. 7'13 On the contrary; in some 
reports, ~1'1s lower limb deep vein thrombosis is the 
most common lesion, followed by superior and 
inferior vena cava thromboses. Lower limb deep vein 
involvement (76%) was the most common presenta- 
tion in our series followed by SVC involvement (10%), 
superficial thrombophlebitis (10%) and IVC thrombo- 
sis (2.5%), respectively. We have not seen any upper 
limb vein involvement. 
There are different considerations about the patho- 
genesis of the vascular complications and the ten- 
dency for thrombosis in BD. Activation of platelets 
and coagulation system by the impairment of the 
intima because of the vasculitis, which is immuno- 
logical in origin, results in hypercoagulability. Some 
authors suggest hat increased blood viscosity and 
decreased prostacyclin are important factors in the 
formation of thrombosis. 15"19 It is claimed that prosta- 
cyclin synthesis is significantly low in patients with 
vascular involvement. It has been suggested that the 
decreased activity of the fibrinolytic system 6"2° or 
hyperfibrinogenesis 21 may cause superficial 
thrombophlebitis. 
Positive Pathergy test and ocular lesions are more 
frequently seen in BD with vascular involvement. 22 
The treatment of BD accompanied with vascular 
lesions remained to be solved. Treatment varies from 
antiagregant agents to intravenous anticoagulation. 
Aspirin treatment is not offered due to low levels of 
prostacyclin i BD. Colchicine, prednisone and hepa- 
rin are still used frequently in the treatment and 
combination of these agents is believed to be the best 
therap~ however these have not been studied in 
controlled trials. The role of cytotoxic agents, such as 
cyclosporine-A, azothipirine and cyclophosphamide 
in treatment ofvascular lesions is not clean The aim of 
treatment should be the determination a d the evalua- 
tion of the risk factors related to the development of
the vascular complications and to decrease or to 
control the complication rates by the early treatment 
of the patients in high risk groups. As the pathophy- 
siology of the BD is clarified, new approaches will be 
available. 22 Some authors uggest that the fibrinolytic 
agents could be used in patients with venous throm- 
bosis. Corticosteroids should be used only in acute 
phases. 6 
In cases of venous occlusion, the prognosis is not 
always poor because of the development of collateral 
veins and recanalisation. 23 If the patient has severe 
collateral insufficiency, surgical intervention may be 
considered. However, reports on this subject are 
limited and there are only two unsuccessful cases of 
thrombectomy reported for superior vena cava throm- 
bosis. 24'25 The results of reconstructive ascular sur- 
gery in patients with BD are not good for venous or 
arterial lesions as there is a high incidence of reocclu- 
sion. Surgical procedures should be avoided in venous 
lesions unless it is absolutely necessary. 26 
In conclusion, venous lesions are encountered more 
frequently than arterial esions in BD. Venous occlu- 
sions are well tolerated because of collateral develop- 
ment and recanalisation of veins. If the patient has 
severe collateral insufficienc~ surgical intervention 
should be the last resort because the results of 
reconstructive surgery are not good due to rethrombo- 
sis. Because vascular complications are found in 
approximately 1/4 of the patients with BD, vascular 
involvement, may be an important parameter for 
diagnosis in patients without the classical triad of 
BD. 
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